Healthcare Industry News: ezetimibe/simvastatin
News Release - March 13, 2006
New Analysis Showed VYTORIN(R) (ezetimibe/simvastatin) Superior to Lipitor(R) in Achieving Lower Levels of LDL (''bad'') Cholesterol, Apolipoprotein B and C-Reactive Protein
Source: Merck-Schering Plough
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.